U.S. Markets closed

Northwest Biotherapeutics, Inc. (NWBO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.172-0.000 (-0.290%)
At close: 3:59PM EDT
People also watch
IMUCGALECLDXIDRATHLD
Full screen
Previous Close0.172
Open0.174
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.171 - 0.177
52 Week Range0.160 - 0.980
Volume995,407
Avg. Volume1,890,303
Market Cap50.78M
Beta1.12
PE Ratio (TTM)-0.31
EPS (TTM)-0.56
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Trade prices are not sourced from all markets
  • NW BIO Announces Registered Direct Offering Of $1.75 Million
    PR Newswire4 days ago

    NW BIO Announces Registered Direct Offering Of $1.75 Million

    BETHESDA, Md., Sept. 20, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $1.75 million. In the transaction, the Company will sell approximately 8.75 million shares of common stock at a purchase price of $0.20 per share.  Additionally, the investors will receive five year warrants to purchase up to approximately 4.375 million shares of common stock with an exercise price of $0.22 per share.

  • Capital Cube19 days ago

    ETFs with exposure to Northwest Biotherapeutics, Inc. : September 6, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Northwest Biotherapeutics, Inc. Here are 5 ETFs with the largest exposure to NWBO-US. Comparing the performance and risk of Northwest Biotherapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • DCVax® Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference
    PR Newswire23 days ago

    DCVax® Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference

    DCVax®-L Phase III GBM Trial & DCVax-Direct Phase I/II Updates; Overview Of A Broader Range Of DC Vax Public Data BETHESDA, Md. , Sept. 1, 2017 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW ...